Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study)

Aim: To assess weight loss associated with liraglutide 3.0 mg treatment in individuals with obesity (body mass index [BMI] >= 30 kg/m(2) ) or overweight (BMI > 27 to <30 kg/m(2) ) in a reimbursed, real-world setting in Switzerland.Materials and methods: ADDRESS was a non-comparative, multicentre, retrospective exposure cohort study in Switzerland, examining weight loss in individuals with obesity or overweight whose treatment was reimbursed (divided into BMI subgroups) or non-reimbursed. The primary outcomes were proportions of participants in the reimbursed cohort achieving predefined weight loss targets with liraglutide 3.0 mg at Week 16 (>= 5% and >= 7% for the lower BMI [28 to <35 kg/m(2) with weight-related comorbidities] and higher BMI [>= 35 kg/m(2) ] subgroups, respectively) and Month 10 (additional >= 5% from Week 16; per Swiss reimbursement criteria).Results: The full analysis set comprised 258 individuals (195 reimbursed; 63 non-reimbursed). In the reimbursed cohort, 139 individuals (71.3%) achieved their weight loss targets at Week 16. Of individuals who met the Week-16 criteria, 43.2% attained an additional 5% weight loss at Month 10. In 162 individuals for whom data were recorded at Month 10, the mean (standard deviation) relative weight loss from baseline to Month 10 was -12.4% (6.4%).Conclusions: Although reimbursement criteria may be difficult to achieve, particularly the additional weight loss of 5% from Week 16 to Month 10, a clinically relevant overall weight loss from baseline to Month 10 was shown in most individuals with obesity or overweight who received liraglutide 3.0 mg.